Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yonghe Medical Group CoFRA:L97 +3.88%84 EV-to-EBITDA is 2.95 as of Aug. 22, 2026, which is 55% below its 10-year median of 6.50. GuruFocus rates FRA:L97 with a GF Score™ of 84/100 and a GF Value™ of €0.22. The stock has 7 warning signs investors should review. Among 512 Healthcare Providers & Services companies, Yonghe Medical Group Co ranks better than 88.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Yonghe Medical Group Co's enterprise value is €78.7 Mil.
Yonghe Medical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €26.7 Mil. Therefore, Yonghe Medical Group Co's EV-to-EBITDA for today is 2.95.
The historical rank and industry rank for Yonghe Medical Group Co's EV-to-EBITDA or its related term are showing as below:
FRA:L97'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.93 Med: 6.5 Max: 30.98
Current: 2.98
During the past 8 years, the highest EV-to-EBITDA of Yonghe Medical Group Co was 30.98. The lowest was -7.93. And the median was 6.50.
FRA:L97's EV-to-EBITDA is ranked better than 88.67% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.6
vs FRA:L97: 2.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Yonghe Medical Group Co (FRA:L97) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Yonghe Medical Group Co's PE Ratio (TTM) for today is calculated as:
Yonghe Medical Group Co's share price for today is €0.268.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Yonghe Medical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Yonghe Medical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yonghe Medical Group Co EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yonghe Medical Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Yonghe Medical Group Co's EV-to-EBITDA falls into.
Yonghe Medical Group Co's current Enterprise Value is €78.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Yonghe Medical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €26.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yonghe Medical Group Co (FRA:L97) has a EV-to-EBITDA of 2.95 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Yonghe Medical Group Co. This is 55% below median its historical median of 6.50. According to the industry distribution chart, Yonghe Medical Group Co ranks #58 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 11.3%.
Is Yonghe Medical Group Co's EV-to-EBITDA too high?
Yonghe Medical Group Co's current EV-to-EBITDA of 2.95 is 55% below median its 10-year median of 6.50. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.60. Yonghe Medical Group Co's value of 2.95 is 72.2% below this industry median. Based on the distribution chart, Yonghe Medical Group Co ranks #58 out of 512 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Yonghe Medical Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Yonghe Medical Group Co's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Yonghe Medical Group Co ranks #58 out of 512 companies for EV-to-EBITDA. This places Yonghe Medical Group Co in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.60. Yonghe Medical Group Co's value of 2.95 is 72.2% below this benchmark. While the company's 10-year median is 6.50 vs. the industry median of 10.60, Yonghe Medical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.60, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yonghe Medical Group Co's current EV-to-EBITDA of 2.95 is 72.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Yonghe Medical Group Co. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yonghe Medical Group Co's current EV-to-EBITDA is 2.95, which is 55% below median its own 10-year median of 6.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yonghe Medical Group Co stock overvalued right now?
Yonghe Medical Group Co (FRA:L97) has a current EV-to-EBITDA of 2.95. The stock's GF Value™ is €0.22, compared to a current price of €0.27 — trading 21.8% above its estimated fair value. The current EV-to-EBITDA is 2.95, which is 55% below median its 10-year median of 6.50 and 72.2% below the Healthcare Providers & Services industry median of 10.60. Yonghe Medical Group Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Yonghe Medical Group Co (FRA:L97), the current EV-to-EBITDA is 2.95 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yonghe Medical Group Co (FRA:L97) Overvalued in 2026?
Based on GuruFocus' analysis, Yonghe Medical Group Co stock appears to be overvalued.
The current stock price of €0.27 is trading 21.8% above its estimated GF Value™ of €0.22.
Key valuation signals for FRA:L97:
EV-to-EBITDA: 2.95 (55% below median its 10-year median of 6.50)
GF Value™: €0.22 vs. price of €0.27 (21.8% above fair value)
Industry Position: 72.2% below the Healthcare Providers & Services median (#58 of 512)
No single metric tells the full story. See the FRA:L97 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yonghe Medical Group Co Ltd is a medical group in China that specializes in providing hair-related healthcare services. The company is principally engaged in the provision of hair transplant services. The company generated the majority of its revenue from hair transplant services. The company offers one-stop hair-related healthcare services covering hair transplants, medical hair care, routine hair restoration, and other ancillary services.
84GF Score
Get the complete analysis for FRA:L97
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L97 has been successfully added to your 
